CGEM insider trading
HealthcareCullinan Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Company website: cullinantherapeutics.com
CGEM insider activity at a glance
FilingIQ has scored 309 insider transactions for CGEM since Jan 7, 2021. The most recent filing in our index is dated May 5, 2026.
Across the full history, 25 open-market purchases
and 190 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CGEM insider trades is 54.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CGEM Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CGEM?
- FilingIQ tracks 309 Form 4 insider transactions for CGEM (Cullinan Therapeutics, Inc.), covering filings from Jan 7, 2021 onwards. 29 of those were filed in the last 90 days.
- Are CGEM insiders net buyers or net sellers?
- Across the full Form 4 history for CGEM, 25 transactions (8%) were open-market purchases and 190 (61%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CGEM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CGEM in?
- Cullinan Therapeutics, Inc. (CGEM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $710.10M.
Methodology & sources
Every CGEM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.